Document:

EX-10.9

 Exhibit 10.9 

REAFFIRMATION AGREEMENT 

This REAFFIRMATION AGREEMENT (this “Reaffirmation”) is made and entered into as of August 9, 2018, by
ENDOLOGIX, INC., a Delaware corporation (“Borrower”), CVD/RMS ACQUISITION CORP., a Delaware corporation (“CVD/RMS”), NELLIX, INC., a Delaware corporation (“Nellix”),
TRIVASCULAR, INC., a California corporation (“TriVascular”), TRIVASCULAR TECHNOLOGIES, INC., a Delaware corporation (“Technologies”), ENDOLOGIX CANADA, LLC, a Delaware limited liability company
(f/k/a TriVascular Canada, LLC) (“Canada”), TRIVASCULAR SALES LLC, a Texas limited liability company (“Sales”) and RMS/ENDOLOGIX SIDEWAYS MERGER CORP., a Delaware corporation
(“Sideways”; together with Borrower, CVD/RMS, Nellix, TriVascular, Technologies, Canada and Sales, individually and collectively, the “Obligors”) in favor of DEERFIELD PRIVATE DESIGN FUND IV, L.P., as Agent
for the Secured Parties. All initially capitalized terms used herein (including in the preamble and recitals hereof) without definition shall have the meanings ascribed thereto in the below-defined Amended and Restated Facility Agreement. 

W I T N E S S E T H: 

WHEREAS, certain Obligors, Agent and the lenders party thereto are parties to that certain Facility Agreement, dated as of
April 3, 2017 (as amended, restated, supplemented, or otherwise modified from time to time prior to the date hereof, the “Existing Facility Agreement”); 

WHEREAS, in connection with the Existing Facility Agreement, each Obligor has executed certain Loan Documents (as such term is defined
in the Existing Facility Agreement) (to the extent that such Loan Documents are not being amended and restated in connection with the Amended and Restated Facility Agreement, each an “Obligor Agreement” and collectively, the
“Obligor Agreements”); 
 WHEREAS, each Obligor, the lenders party thereto as “Lenders” (each of such
Lenders, together with their respective successors and permitted assigns, are referred to hereinafter as a “Lender”), and Agent are concurrently herewith entering into that certain Amended and Restated Facility Agreement (as
amended, restated, supplemented, or otherwise modified from time to time, the “Amended and Restated Facility Agreement”), whereby the Lenders have agreed to make certain financial accommodations available to the Obligors from time
to time pursuant to the terms and conditions thereof and the Agent and the Lenders have agreed to make certain amendments to the Existing Facility Agreement and permit the ABL Credit Facility and the ABL Debt Documents on the terms set forth in the
Amended and Restated Facility Agreement and other Loan Documents; and 
 WHEREAS, in connection with the execution and delivery of
the Amended and Restated Facility Agreement and any other Loan Documents in connection therewith, each Obligor desires to expressly ratify, reaffirm and confirm each Obligor Agreement executed by such Obligor and the rights granted thereby in favor
of Agent (for its benefit and the benefit of the other Secured Parties) and to agree and acknowledge the joint and several liability between all Obligors of the Obligations (including any Non-Callable Make
Whole Amount, any CoC Fee and the Exit Payment). 
 NOW, THEREFORE, in consideration of the foregoing premises and for other good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows: 
 1. Each
Obligor hereby ratifies, reaffirms and confirms each Obligor Agreement to which it is a party, and its payment and performance obligations, contingent or otherwise, thereunder and does hereby acknowledge that any rights granted thereby in favor of
Agent (for its benefit and the benefit of 

 
the other Secured Parties) are and shall remain in full force and effect subsequent to the Agreement Date, as though each such Obligor Agreement was executed in full by such Obligor as of the
date hereof, subject to any amendments made to the Loan Documents on the Agreement Date. Each Obligor also hereby ratifies, reaffirms and confirms all prior and/or concurrent grants of security interests and Liens or “control” (within the
meaning of Articles 8 and 9 under the applicable UCC, “Control”) in favor of Agent or any other Secured Party in all of such Obligor’s right, title, and interest in, to, and under the Collateral under each Loan Document
(including each Obligor Agreement), subject to any amendments made to the Loan Documents on the Agreement Date. 
 2. Each Obligor confirms
and agrees that to the extent that any such Obligor Agreement purports to assign or pledge to Agent or any Secured Party or to grant to Agent or any other Secured Party a security interest in or Lien on, any collateral (including, without
limitation, the Collateral) or to provide Control to Agent or any other Secured Party as security for the obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole
Amount, any CoC Fee and the Exit Payment) as defined in any Loan Document including any Obligor Agreement) of any Obligor or any other Loan Party, as the case may be, from time to time existing in respect of the Amended and Restated Facility
Agreement, or any Loan Document, such pledge or assignment or grant of the security interest or Lien or Control is hereby ratified, reaffirmed and confirmed in all respects, and shall constitute and be deemed a pledge or assignment or grant of the
security interest or Lien or Control under the Amended and Restated Facility Agreement and the Loan Documents subject to any amendments made to the Loan Documents on the Agreement Date. Without limiting the generality of the foregoing, each Obligor
hereby confirms and agrees that any security interest or Lien granted (or Control provided) in any Obligor Agreement shall secure the obligations (including, without limitation, the Obligations (including any
Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) as defined in any Loan Document including any Obligor Agreement) under the Amended and Restated Facility Agreement and the other Loan
Documents, as applicable. Each Obligor hereby further ratifies, reaffirms and confirms the validity and enforceability of all of the Liens and security interests heretofore granted and Control provided, pursuant to and in connection with any Obligor
Agreement or any other Loan Document, to Agent or any other Secured Party, as collateral security for the obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole
Amount, any CoC Fee and the Exit Payment)) under the Loan Documents in accordance with their respective terms, and acknowledges that all of such Liens and security interests and Control, and all Collateral heretofore pledged as security for such
obligations (including, without limitation, the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment)), continue to be and remain collateral for such obligations
(including, without limitation, Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment)) from and after the date hereof subject to any amendments made to the Loan Documents
on the Agreement Date. 
 3. Upon and after the effectiveness of this Reaffirmation, each Obligor confirms and agrees that each reference in
any Obligor Agreement to (i) “the Facility Agreement” or words of like import referring to the Amended and Restated Facility Agreement shall mean and be a reference to the Amended and Restated Facility Agreement and (ii) each
reference to any other agreement, instrument or document that is an Existing Loan Document that is being amended or amended and restated in connection with the amendment and restatement of the Existing Facility Agreement shall mean and be a
reference to such agreement, instrument or document as amended or amended and restated. 
 4. Each Obligor hereby further acknowledges that
Agent’s solicitation of ratification, reaffirmation and confirmation of each such Obligor Agreement pursuant to this Reaffirmation is not a condition to the continued effectiveness of each such Obligor Agreement. 

  
 2 

 5. With respect to all Obligations (including, without limitation, all obligations under
each Obligor Agreement and each Loan Document, including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment), each Obligor accepts, reaffirms, confirms and ratifies and agrees to joint and
several liability hereunder, thereunder and under the other Loan Documents and the Obligor Agreements, pursuant to the terms hereof and thereof, in consideration of the financial accommodations to be provided by the Secured Parties under the Amended
and Restated Facility Agreement and the other Loan Documents, for the mutual benefit, directly and indirectly, of each Obligor and in consideration of the undertakings of the other Obligors to accept joint and several liability for the Obligations
(including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment). Notwithstanding anything to the contrary in any Existing Loan Document, Obligor Agreement or any Loan Document, all Obligors
hereby reaffirm, confirm and agree that all of the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) are joint and several among the Obligors, pursuant to the terms
of the Loan Documents. If and to the extent that any Obligor shall fail to make any payment with respect to any of the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit
Payment) as and when due or to perform any of the Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) in accordance with the terms of the applicable Loan Documents and
Obligor Agreements, then in each such event the other Obligors will make such payment with respect to, or perform, such Obligations until such time as all of the Obligations (including any Non-Callable Make
Whole Amount, any CoC Fee and the Exit Payment) are paid in full (subject to the second sentence of Section 6.22 to the Amended and Restated Facility Agreement), pursuant to the terms of the Loan Documents. The Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) of each Obligor under the provisions of this Section 5 constitute the absolute and unconditional, full recourse Obligations (including any Non-Callable Make Whole Amount, any CoC Fee and the Exit Payment) of each Obligor enforceable against each Obligor to the full extent of its properties and assets, irrespective of the validity, regularity or
enforceability of the provisions of this Reaffirmation (other than this sentence of this Section 5) or any other circumstances whatsoever but subject to the terms of the Loan Documents. 

6. This Reaffirmation is a Loan Document. This Reaffirmation may be executed in several counterparts, and by each party on separate
counterparts, each of which and any photocopies, facsimile copies and other electronic methods of transmission thereof shall be deemed an original, but all of which together shall constitute one and the same agreement. 

7. THIS REAFFIRMATION SHALL BE SUBJECT TO THE PROVISIONS REGARDING GOVERNING LAW, CONSENT TO JURISDICITION AND WAIVER OF JURY TRIAL SET FORTH
IN SECTION 6.4 OF THE AMENDED AND RESTATED FACILITY AGREEMENT, AND SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, MUTATIS MUTANDIS. 

8. As of the date hereof, each Obligor, for itself and on behalf of its successors, assigns, and officers, directors, employees, agents and
attorneys, and any Person acting for or on behalf of, or claiming through it, hereby waives, releases, remises and forever discharges each Secured Party, each of their respective Affiliates and successors in title, and past, present and future
officers, directors, employees, limited partners, general partners, investors, attorneys, assigns, subsidiaries, shareholders, trustees, agents and other professionals of the foregoing entities and all other Persons and entities to whom any Secured
Party would be liable if such Persons were found to be liable to such Obligor (each a “Releasee” and collectively, the “Releasees”), from any and all past, present and future claims, suits, liens, lawsuits, amounts
paid in settlement, debts, deficiencies, disbursements, demands, obligations, liabilities, causes of action, damages, losses, costs and expenses of any kind or character, whether based in equity, law, contract, tort, implied or express warranty,
strict liability, criminal or civil statute or common law (each a “Claim” and collectively, the “Claims”), whether known or unknown, fixed or contingent, direct, 

  
 3 

 
indirect, or derivative, asserted or unasserted, matured or unmatured, foreseen or unforeseen, past or present, liquidated or unliquidated, suspected or unsuspected, which such Obligor ever had
from the beginning of the world until the date hereof against any such Releasee which relates, directly or indirectly to the Amended and Restated Facility Agreement, any other Loan Document (as defined therein and including any Obligor Agreement),
the Stock owned by any Releasee or to any acts or omissions of any such Releasee with respect to the Amended and Restated Facility Agreement or any other Loan Document (as defined therein and including, without limitation, any Obligor Agreement) or
any Stock owned by any Releasee, or to the lender-borrower relationship evidenced by the Loan Documents (as defined in the Amended and Restated Facility Agreement and including any Obligor Agreement) or the Warrant/Stock holder or owner-issuer of
Warrant/Stock holder issuer, expressly excluding the duties and obligations of Agent and the Lenders set forth in the Amended and Restated Facility Agreement and the other Loan Documents to occur solely after the Agreement Date. As to each and every
Claim released hereunder, each Obligor hereby agrees, represents and warrants that it has received the advice of legal counsel with regard to the releases contained herein, and having been so advised, specifically waives the benefit of the
provisions of Section 1542 of the Civil Code of California which provides as follows: 
 “A GENERAL RELEASE DOES NOT EXTEND TO
CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.” 

As to each and every Claim released hereunder, each Obligor also waives the benefit of each other similar provision of applicable federal or
state law (including without limitation the laws of the State of New York), if any, pertaining to general releases after having been advised by legal counsel to such Obligor with respect thereto. 

Each Obligor acknowledges that it may hereafter discover facts different from or in addition to those now known or believed to be true with
respect to such Claims and agrees that this Reaffirmation shall be and remain effective in all respects notwithstanding any such differences or additional facts. Each Obligor understands, acknowledges and agrees that the release set forth above may
be pleaded as a full and complete defense and may be used as a basis for an injunction against any action, suit or other proceeding which may be instituted, prosecuted or attempted in breach of the provisions of such release. 

Each Obligor hereby agrees, represents, and warrants that (a) such party has not voluntarily, by operation of law or otherwise, assigned,
conveyed, transferred or encumbered, either directly or indirectly, in whole or in part, any right to or interest in any of the Claims released pursuant to this Section 8; (b) this Reaffirmation has been entered into without force or duress, of
the free will of each Obligor, and the decision of such undersigned to enter into this Reaffirmation is a fully informed decision and such undersigned is aware of all legal and other ramifications of each such decision; and (c) such Obligor has
read and understands this Reaffirmation (including, without limitation, the release granted in this Section 8), has consulted with and been represented by independent legal counsel of its own choosing in negotiations for and the preparation of
this Reaffirmation, has read this Reaffirmation in full and final form, and has been advised by its counsel of its rights and obligations hereunder 

Each Obligor, for itself and on behalf of its successors, assigns, and Affiliates and their respective officers, directors, employees, agents
and attorneys, and any Person acting for or on behalf of, or claiming through it, hereby absolutely, unconditionally and irrevocably, covenants and agrees with and in favor of each Releasee above that it will not sue (at law, in equity, in any
regulatory proceeding or otherwise) any Releasee on the basis of any Claim released, remised and discharged by such Person pursuant to the above release in this Section 8. Each Obligor further agrees that it shall not dispute the

  
 4 

 
validity or enforceability of the Amended and Restated Facility Agreement, any of the other Loan Documents (including, without limitation, each Obligor Agreement), or any of its obligations
thereunder, or the creation, validity, perfection, priority, enforceability or the extent of Agent’s security interest or Lien on any item of Collateral under the Amended and Restated Facility Agreement and the other Loan Documents (including
each Obligor Agreement) or the providing of any Control under any Control Agreement or any other Loan Document. If any Obligor violates the foregoing covenant, such Obligor, for itself and its successors, assigns and legal representatives, agrees to
pay, in addition to such other damages as any Releasee may sustain as a result of such violation, all attorneys’ fees, expenses and costs and any other fees, expenses and costs incurred by such Releasee as a result of such violation. 

[remainder of page intentionally left blank] 

  
 5 

 IN WITNESS WHEREOF, Obligor has caused this Reaffirmation to be duly executed as of
the date first above written. 
  

					
	OBLIGORS:	 	ENDOLOGIX, INC.,
		 	a Delaware corporation
			
		 	By:	  	 /s/ Vaseem Mahboob

		 	Name: Vaseem Mahboob
		 	Title: Chief Financial Officer 
		
		 	 CVD/RMS ACQUISITION CORP., 

a Delaware corporation

			
		 	By:	  	 /s/ Vaseem Mahboob

		 	Name: Vaseem Mahboob
		 	Title: Chief Financial Officer and Secretary
		
		 	 NELLIX, INC.,
 a Delaware
corporation

			
		 	By:	  	 /s/ Vaseem Mahboob

		 	Name: Vaseem Mahboob
		 	Title: Chief Financial Officer and Secretary
		
		 	 TRIVASCULAR, INC.,
 a
California corporation 

			
		 	By:	  	 /s/ Vaseem Mahboob

		 	Name: Vaseem Mahboob
		 	Title: Chief Financial Officer and Secretary
		
		 	 TRIVASCULAR TECHNOLOGIES, INC.,

a Delaware corporation

			
		 	By:	  	 /s/ Vaseem Mahboob

		 	Name: Vaseem Mahboob
		 	Title: Chief Financial Officer and Secretary

 [SIGNATURE PAGE TO REAFFIRMATION AGREEMENT 

(AMENDED AND RESTATED FACILITY AGREEMENT)] 

 
			
	 ENDOLOGIX CANADA, LLC,
 a
Delaware limited liability company

		
	By:	 	 /s/ Vaseem Mahboob

	Name: Vaseem Mahboob
	Title: Chief Financial Officer and Secretary
	
	 TRIVASCULAR SALES LLC,
 a
Texas limited liability company

		
	By:	 	 /s/ Vaseem Mahboob

	Name: Vaseem Mahboob
	Title: Chief Financial Officer and Secretary
	
	 RMS/ENDOLOGIX SIDEWAYS MERGER CORP.,

a Delaware corporation

		
	By:	 	 /s/ Vaseem Mahboob

	Name: Vaseem Mahboob
	Title: Chief Financial Officer and Secretary

 [SIGNATURE PAGE TO REAFFIRMATION AGREEMENT 

(AMENDED AND RESTATED FACILITY AGREEMENT)] 

 AGENT: 
  

			
	 DEERFIELD PRIVATE DESIGN FUND IV, L.P.
  

By: Deerfield Mgmt IV, L.P., General Partner
  

By: J.E. Flynn Capital IV, LLC, General Partner

		
	By:	 	 /s/ David J. Clark

	 Name:
 Title:
	 	 David J. Clark
 Authorized
Signatory

 [SIGNATURE PAGE TO REAFFIRMATION AGREEMENT 

(AMENDED AND RESTATED FACILITY AGREEMENT)]EX-10.10

 Exhibit 10.10 

Execution Version 
 PATENT
SECURITY AGREEMENT 
 This PATENT SECURITY AGREEMENT (this “Patent Security Agreement”) is made this 9th day of August, 2018, by and among the Grantors listed on the signature pages hereof (collectively, jointly and severally, “Grantors” and each individually
“Grantor”), and DEERFIELD ELGX REVOLVER, LLC, a Delaware limited liability company, in its capacity as agent for each member of the Lender Group (in such capacity, together with its successors and assigns in such capacity,
“Agent”). 
 W I T N E S S E T H: 

WHEREAS, pursuant to that certain Credit Agreement dated as of August 9, 2018 (as amended, restated, supplemented, or otherwise modified
from time to time, the “Credit Agreement”) by and among ENDOLOGIX, INC., a Delaware corporation (“Endologix”), each of its direct and indirect Subsidiaries set forth on the signature pages thereto and any
additional borrower that may thereafter be added to the Credit Agreement (individually as a “Borrower”, and collectively with any entities that become party thereto as Borrower and each of their successors and permitted assigns, the
“Borrowers”), the lenders party thereto as “Lenders” (such Lenders, together with their respective successors and assigns in such capacity, each, individually, a “Lender” and, collectively, the
“Lenders”), and Agent, the Lender Group has agreed to make certain financial accommodations available to the Borrowers from time to time pursuant to the terms and conditions thereof; 

WHEREAS, the members of the Lender Group are willing to make the financial accommodations to the Borrowers as provided for in the Credit
Agreement and the other Loan Documents, but only upon the condition, among others, that Grantors shall have executed and delivered to Agent, for the benefit of the Lender Group, that certain Guaranty and Security Agreement, dated as of
August 9, 2018 (including all annexes, exhibits or schedules thereto, as from time to time amended, restated, supplemented or otherwise modified, the “Guaranty and Security Agreement”); and 

WHEREAS, pursuant to the Guaranty and Security Agreement, Grantors are required to execute and deliver to Agent, for the benefit of the Lender
Group, this Patent Security Agreement. 
 NOW, THEREFORE, in consideration of the premises and mutual covenants herein contained and for
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor hereby agrees as follows: 

1. DEFINED TERMS. All initially capitalized terms used but not otherwise defined herein have the meanings given to them in the Guaranty
and Security Agreement or, if not defined therein, in the Credit Agreement, and this Patent Security Agreement shall be subject to the rules of construction set forth in Section 1.04 of the Credit Agreement, which rules of construction are
incorporated herein by this reference, mutatis mutandis. 
 2. GRANT OF SECURITY INTEREST IN PATENT COLLATERAL. Each Grantor
hereby unconditionally grants, assigns, and pledges to Agent, for the benefit of each member of the Lender Group, to secure the Secured Obligations, a continuing security interest 

  
 1 

 
(referred to in this Patent Security Agreement as the “Security Interest”) in all of such Grantor’s right, title and interest in and to the following, whether now owned or
hereafter acquired or arising (collectively, the “Patent Collateral”): 
 (a) all of its Patents and Patent Intellectual
Property Licenses to which it is a party including those referred to on Schedule I; 
 (b) all divisionals, continuations, continuations-in-part, reissues, reexaminations, or extensions of the foregoing; and 

(c) all products and proceeds of the foregoing, including any claim by such Grantor against third parties for past, present or future
infringement of any Patent or any Patent exclusively licensed under any Intellectual Property License, including the right to receive damages, or right to receive license fees, royalties, and other compensation under any Patent Intellectual Property
License. 
 3. SECURITY FOR SECURED OBLIGATIONS. This Patent Security Agreement and the Security Interest created hereby secures the
payment and performance of the Secured Obligations, whether now existing or arising hereafter. Without limiting the generality of the foregoing, this Patent Security Agreement secures the payment of all amounts which constitute part of the Secured
Obligations and would be owed by Grantors, or any of them, to Agent, the other members of the Lender Group or any of them, whether or not they are unenforceable or not allowable due to the existence of an Insolvency Proceeding involving any Grantor.

 4. PROTECTION OF PATENT SECURITY INTEREST BY GRANTORS. Each Grantor shall, at its sole cost, expense and risk, in connection with
the operation of its business, comply with the requirements set forth in Section 6 of the Guaranty and Security Agreement in respect of the Patent Collateral. 

5. REPRESENTATIONS AND WARRANTIES. Each Grantor represents and warrants that: 

(a) Schedule I hereto is a true, correct and complete list of all Patents and Patent Intellectual Property Licenses in which each Grantor
purports to have an ownership or license interest. 
 (b) Such Grantor has the legal right and authority to enter into this Patent Security
Agreement and perform its terms. 
 (c) If such Grantor amends its name, such Grantor shall provide copies of such amendment documentation to
Agent and shall, if necessary, re-register such Grantor’s Patents and Patent Intellectual Property Licenses with the appropriate Governmental Authority and shall execute and deliver such agreements or
documentation as Agent shall reasonably request in writing to maintain a perfected first priority security interest in the Patent Collateral subject to Permitted Liens. 

6. SECURITY AGREEMENT. The Security Interest in the Collateral granted pursuant to this Patent Security Agreement is granted in
conjunction with the security interests 

  
 2 

 
granted to Agent, for the benefit of the Lender Group, pursuant to the Guaranty and Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of Agent with
respect to the Security Interest in the Patent Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.
To the extent there is any inconsistency between this Patent Security Agreement and the Guaranty and Security Agreement, the Guaranty and Security Agreement shall control. 

7. AUTHORIZATION TO SUPPLEMENT. If any Grantor shall obtain rights to any new patent application or issued patent or become entitled to
the benefit of any patent application or patent for any divisional, continuation, continuation-in-part, reissue, or reexamination of any existing patent or patent
application, the provisions of this Patent Security Agreement shall automatically apply thereto. Each Grantor shall notify Agent of applications filed for the registration of any Patents with the United States Patent Office in accordance with
Section 5.7(g) of the Guaranty and Security Agreement. Without limiting Grantors’ obligations under this Section, Grantors hereby authorize Agent unilaterally to modify this Patent Security Agreement by amending Schedule I to
include any such new patent rights of each Grantor. Notwithstanding the foregoing, no failure to so modify this Patent Security Agreement or amend Schedule I shall in any way affect, invalidate or detract from Agent’s continuing security
interest in all Collateral, whether or not listed on Schedule I. 
 8. NO VIOLATION OF LOAN DOCUMENTS. The representations,
warranties or covenants contained herein are supplemental to those representations, warranties and covenants contained in the other Loan Documents, and shall not be deemed to modify any such representation, warranty or covenant contained in any
other Loan Document. 
 9. GRANTOR’S RIGHTS TO ENFORCE PATENTS. Prior to Agent’s giving of notice to Grantor following the
occurrence and during the continuance of an Event of Default, such Grantor shall have the exclusive right to sue for past, present and future infringement of the Patent Collateral, including the right to seek injunctions and/or money damages, in an
effort by such Grantor to protect the Patent Collateral against encroachment by third parties, provided, however, that: 
 (a) Any money
damages awarded or received by such Grantor on account of such suit (or the threat of such suit) shall constitute Patent Collateral. 
 (b)
Any damages recovered in any action pursuant to this Section, net of costs and attorneys’ fees reasonably incurred, shall be applied in accordance with the Credit Agreement and the Guaranty and Security Agreement. 

(c) Following the occurrence and during the continuance of any Event of Default, Agent, by notice to any Grantor may terminate or limit such
Grantor’s rights under this Section 9. 
 10. RIGHTS UPON DEFAULT. Upon the occurrence and during the continuance of any
Event of Default, Agent may exercise all rights and remedies as provided for in the Guaranty and Security Agreement. 

  
 3 

 11. NO LIMITATION; LOAN DOCUMENTS. This Patent Security Agreement has been executed
and delivered by each Grantor for the purpose of recording the security interest granted to Agent with respect to the Patent Collateral with the United States Patent Office. The security interest granted hereby has been granted as a supplement to,
and not in limitation of, the security interest granted to Agent, for the benefit of the Lender Group, under the Guaranty and Security Agreement and the other Loan Documents. The other Loan Documents (and all rights and remedies of Grantor, Agent,
and Lenders thereunder) shall remain in full force and effect in accordance with their terms. 
 12. TERMINATION; RELEASE OF PATENT
COLLATERAL. This Patent Security Agreement and all obligations of each Grantor and Agent hereunder shall terminate on the date upon which the Obligations have been Paid in Full. Upon termination of this Patent Security Agreement, Agent shall, at
the reasonable expense of the Grantor, take such actions required by the Credit Agreement or the Guaranty and Security Agreement or as otherwise reasonably requested by Grantor to release its security interest in the Patent Collateral. 

13. BINDING EFFECT; BENEFITS. This Patent Security Agreement shall be binding upon each Grantor and its successors and assigns, and
shall inure to the benefit of Agent, Lenders and their respective successors and assigns. 
 14. COUNTERPARTS. This Patent Security
Agreement is a Loan Document. This Patent Security Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of
which, when taken together, shall constitute but one and the same Patent Security Agreement. Delivery of an executed counterpart of this Patent Security Agreement by telefacsimile or other electronic method of transmission shall be equally as
effective as delivery of an original executed counterpart of this Patent Security Agreement. Any party delivering an executed counterpart of this Patent Security Agreement by telefacsimile or other electronic method of transmission also shall
deliver an original executed counterpart of this Patent Security Agreement but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Patent Security Agreement. 

15. CHOICE OF LAW AND VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE PROVISION. THIS PATENT SECURITY AGREEMENT SHALL BE SUBJECT TO THE
PROVISIONS REGARDING CHOICE OF LAW AND VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE SET FORTH IN SECTIONS 8.11 AND 8.12 OF THE GUARANTY AND SECURITY AGREEMENT, AND SUCH PROVISIONS ARE INCORPORATED HEREIN BY THIS REFERENCE, MUTATIS
MUTANDIS. 
 [signature page follows] 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have caused this Patent Security Agreement to be
executed and delivered as of the day and year first above written. 
  

							
	GRANTORS:	 		 	ENDOLOGIX, INC.
				
		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 	Name: Vaseem Mahboob

		 		 	Title: Chief Financial Officer
			
		 		 	NELLIX, INC.
				
		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 	Name: Vaseem Mahboob
		 		 	Title: Chief Financial Officer and Secretary
			
		 		 	TRIVASCULAR, INC.
				
		 		 	By:	 	 /s/ Vaseem Mahboob

		 		 	Name: Vaseem Mahboob
		 		 	Title: Chief Financial Officer and Secretary

 [SIGNATURE PAGE TO PATENT SECURITY AGREEMENT] 

 IN WITNESS WHEREOF, the parties hereto have caused this Patent Security Agreement to be
executed and delivered as of the day and year first above written. 
  

							
		 		 	ACCEPTED AND ACKNOWLEDGED BY:
			
	AGENT:	 		 	DEERFIELD ELGX REVOLVER, LLC
		 		 	by: Deerfield Management Company, L.P. (Series C), Manager
		 		 	By: Flynn Management LLC, General Partner
				
		 		 	By:	 	 /s/ David J. Clark

		 		 	Name: David J. Clark
		 		 	Title: Authorized Signatory

  
 6 

 SCHEDULE I 

to 
 PATENT SECURITY AGREEMENT 

Patents 
  

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC.	  	US	  	Stent graft	  	US9757262B2	  	US13943246A	  	2013-07-16
						
	ENDOLOGIX INC.	  	US	  	Catheter system and methods of using same	  	US9700701B2	  	US13544426A	  	2012-07-09
						
	ENDOLOGIX INC.	  	US	  	Catheter system and methods of using same	  	US9687374B2	  	US15379268A	  	2016-12-14
						
	ENDOLOGIX INC.	  	US	  	Percutaneous method and device to treat dissections	  	US9579103B2	  	US12771711A	  	2010-04-30

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC.	  	US	  	Catheter system and methods of using same	  	US9549835B2	  	US14462485A	  	2014-08-18
						
	ENDOLOGIX INC.	  	US	  	Method and system for treating aneurysms	  	US9415195B2	  	US13441762A	  	2012-04-06
						
	ENDOLOGIX INC.	  	US	  	Devices and methods to treat vascular dissections	  	US9393100B2	  	US13988175A	  	2013-05-17
						
	ENDOLOGIX INC.	  	US	  	Method for forming materials in situ within a medical device	  	US9289536B2	  	US14201332A	  	2014-03-07
						
	ENDOLOGIX INC.	  	US	  	Apparatus and method of placement of a graft or graft system	  	US9149381B2	  	US14172126A	  	2014-02-04

  
 2 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC.	  	US	  	Stent graft	  	US8821564B2	  	US13397952A	  	2012-02-16
						
	ENDOLOGIX INC.	  	US	  	Apparatus and methods for repairing aneurysms	  	US8814928B2	  	US12616928A	  	2009-11-12
						
	ENDOLOGIX INC.	  	US	  	Catheter system and methods of using same	  	US8808350B2	  	US13408952A	  	2012-02-29
						
	ENDOLOGIX INC.	  	US	  	Graft systems having semi-permeable filling structures and methods for their use	  	US8801768B2	  	US13355705A	  	2012-01-23
						
	ENDOLOGIX INC	  	US	  	Bifurcated graft deployment systems and methods	  	US8764812B2	  	US13745682A	  	2013-01-18

  
 3 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC.	  	US	  	Apparatus and method of placement of a graft or graft system	  	US8672989B2	  	US13546950A	  	2012-07-11
						
	ENDOLOGIX INC.	  	US	  	Graft deployment system	  	US8568466B2	  	US13269332A	  	2011-10-07
						
	ENDOLOGIX INC.	  	US	  	Dual concentric guidewire and methods of bifurcated graft deployment	  	US8523931B2	  	US11623022A	  	2007-01-12
						
	ENDOLOGIX INC.	  	US	  	Stent graft	  	US8491646B2	  	US12837398A	  	2010-07-15
						
	ENDOLOGIX INC.	  	US	  	Endolumenal vascular prosthesis with neointima inhibiting polymeric sleeve	  	US8377110B2	  	US10820455A	  	2004-04-08

  
 4 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC.	  	US	  	Bifurcated graft deployment systems and methods	  	US8357192B2	  	US13046541A	  	2011-03-11
						
	ENDOLOGIX INC.	  	US	  	Bifurcated graft deployment systems and methods	  	US8236040B2	  	US12101863A	  	2008-04-11
						
	ENDOLOGIX INC.	  	US	  	Catheter system and methods of using same	  	US8216295B2	  	US12496446A	  	2009-07-01
						
	ENDOLOGIX INC.	  	US	  	Apparatus and method of placement of a graft or graft system	  	US8221494B2	  	US12390346A	  	2009-02-20
						
	ENDOLOGIX INC.	  	US	  	Methods and systems for endovascular aneurysm treatment	  	US8182525B2	  	US12421297A	  	2009-04-09

  
 5 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC.	  	US	  	Single puncture bifurcation graft deployment system	  	US8167925B2	  	US12732095A	  	2010-03-25
						
	ENDOLOGIX INC.	  	US	  	Bifurcation graft deployment catheter	  	US8147535B2	  	US11189101A	  	2005-07-25
						
	ENDOLOGIX INC.	  	US	  	Material for creating multi-layered films and methods for making the same	  	US8133559B2	  	US13100483A	  	2011-05-04
						
	ENDOLOGIX INC.	  	US	  	Stent graft	  	US8118856B2	  	US12844266A	  	2010-07-27
						
	ENDOLOGIX INC.	  	US	  	Graft systems having filling structures supported by scaffolds and methods for their use	  	US8048145B2	  	US11413460A	  	2006-04-28

  
 6 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC.	  	US	  	Graft deployment system	  	US8034100B2	  	US10722367A	  	2003-11-25
						
	ENDOLOGIX INC.	  	US	  	Material for creating multi-layered films and methods for making the same	  	US7951448B2	  	US12858274A	  	2010-08-17
						
	ENDOLOGIX INC	  	US	  	Self expanding bifurcated endovascular prosthesis	  	US7892277B2	  	US11417883A	  	2006-05-03
						
	ENDOLOGIX INC.	  	US	  	Material for creating multi-layered films and methods for making the same	  	US7790273B2	  	US11752750A	  	2007-05-23
						
	ENDOLOGIX INC.	  	US	  	Devices for repairing aneurysms	  	US7682383B2	  	US10481386A	  	2004-06-14

  
 7 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC.	  	US	  	System and methods for endovascular aneurysm treatment	  	US7666220B2	  	US11482503A	  	2006-07-07
						
	ENDOLOGIX INC.	  	US	  	Methods and systems for endovascular aneurysm treatment	  	US7530988B2	  	US11187471A	  	2005-07-22
						
	ENDOLOGIX INC	  	US	  	Self expanding bifurcated endovascular prosthesis	  	US7520895B2	  	US10119525A	  	2002-04-08
						
	ENDOLOGIX INC	  	US	  	Bifurcation graft deployment catheter	  	US6953475B2	  	US10675060A	  	2003-09-30
						
	ENDOLOGIX INC.	  	US	  	Implantable vascular graft	  	US6733523B2	  	US09891620A	  	2001-06-26

  
 8 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC	  	US	  	Single puncture bifurcation graft deployment system	  	US6663665B2	  	US09795993A	  	2001-02-28
						
	ENDOLOGIX INC.	  	US	  	Bifurcation graft deployment catheter	  	US6660030B2	  	US09747094A	  	2000-12-22
						
	ENDOLOGIX INC	  	US	  	Endoluminal vascular prosthesis	  	US6508835B1	  	US09723979A	  	2000-11-28
						
	ENDOLOGIX INC.	  	US	  	Bifurcation graft deployment catheter	  	US6500202B1	  	US09525778A	  	2000-03-15
						
	ENDOLOGIX INC.	  	US	  	Dual wire placement catheter	  	US6440161B1	  	US09348356A	  	1999-07-07

  
 9 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC.	  	US	  	Single puncture bifurcation graft deployment system	  	US6261316B1	  	US09266661A	  	1999-03-11
						
	ENDOLOGIX INC.	  	US	  	Articulating bifurcation graft	  	US6197049B1	  	US09251363A	  	1999-02-17
						
	ENDOLOGIX INC.	  	US	  	Endoluminal vascular prosthesis	  	US6187036B1	  	US09210280A	  	1998-12-11
						
	ENDOLOGIX INC.	  	US	  	Segmented stent for flexible stent delivery system	  	US6187034B1	  	US09229856A	  	1999-01-13
						
	ENDOLOGIX INC.	  	US	  	Endoluminal vascular prosthesis	  	US6077296A	  	US0934689A	  	1998-03-04

  
 10 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC.	  	US	  	Stent delivery system featuring a flexible balloon	  	US6022359A	  	US09229519A	  	1999-01-13
						
	ENDOLOGIX INC.	  	US	  	Radially expandable stent featuring accordion stops	  	US5931866A	  	US09028305A	  	1998-02-24
						
	ENDOLOGIX INC.	  	US	  	DUAL INFLATABLE ARTERIAL PROSTHESIS	  	US20180021045A1	  	US15540246A	  	2017-06-27
						
	ENDOLOGIX INC.	  	US	  	CATHETER SYSTEM AND METHODS OF USING SAME	  	US20170304098A1	  	US15632064A	  	2017-06-23
						
	ENDOLOGIX INC.	  	US	  	CATHETER SYSTEM AND METHODS OF USING SAME	  	US20170296791A1	  	US15639028A	  	2017-06-30

  
 11 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC	  	US	  	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	  	US20170266025A1	  	US15610242A	  	2017-05-31
						
	ENDOLOGIX INC.	  	US	  	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	  	US20170239035A1	  	US15310198A	  	2016-11-10
						
	ENDOLOGIX INC.	  	US	  	METHODS AND SYSTEMS FOR ANEURYSM TREATMENT USING FILLING STRUCTURES	  	US20170238937A1	  	US15438682A	  	2017-02-21
						
	ENDOLOGIX INC	  	US	  	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	  	US20170128246A1	  	US15414499A	  	2017-01-24
						
	ENDOLOGIX INC	  	US	  	METHOD AND SYSTEM FOR TREATING ANEURYSMS	  	US20170007263A1	  	US15205365A	  	2016-07-08

  
 12 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC.	  	US	  	METHOD FOR FORMING HYDROGELS AND MATERIALS THEREFOR	  	US20160367731A1	  	US15256462A	  	2016-09-02
						
	ENDOLOGIX INC.	  	US	  	DEVICES AND METHODS TO TREAT VASCULAR DISSECTIONS	  	US20160302798A1	  	US15194159A	  	2016-06-27
						
	ENDOLOGIX INC.	  	US	  	SYSTEMS AND METHODS FOR FORMING MATERIALS IN SITU WITHIN A MEDICAL DEVICE	  	US20160030051A1	  	US14776385A	  	2015-09-14
						
	ENDOLOGIX INC	  	US	  	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	  	US20150366688A1	  	US14840428A	  	2015-08-31
						
	ENDOLOGIX INC.	  	US	  	METHOD AND SYSTEM FOR TREATING ANEURYSMS	  	US20150250989A1	  	US14717938A	  	2015-05-20

  
 13 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC.	  	US	  	FENESTRATED PROSTHESIS	  	US20150173923A1	  	US14581675A	  	2014-12-23
						
	ENDOLOGIX INC.	  	US	  	Apparatus and Methods for Repairing Aneurysms	  	US20150012081A1	  	US14330812A	  	2014-07-14
						
	ENDOLOGIX INC.	  	US	  	STENT GRAFT	  	US9907642	  	US14461308A	  	2014-08-15
						
	ENDOLOGIX INC	  	US	  	ENDOLUMENAL VASCULAR PROSTHESIS WITH NEOINTIMA INHIBITING POLYMERIC SLEEVE	  	US20130253638A1	  	US13731908A	  	2012-12-31
						
	ENDOLOGIX INC.	  	US	  	Methods and Systems for Treating Aneurysms	  	US20120184982A1	  	US13354094A	  	2012-01-19

  
 14 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC.	  	US	  	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	  	US20120109279A1	  	US13287907A	  	2011-11-02
						
	ENDOLOGIX INC.	  	US	  	FILLING STRUCTURE FOR A GRAFT SYSTEM AND METHODS OF USE	  	US20110276078A1	  	US12966852A	  	2010-12-13
						
	ENDOLOGIX INC	  	US	  	SELF EXPANDING BIFURCATED ENDOVASCULAR PROSTHESIS	  	US20110224782A1	  	US13027077A	  	2011-02-14
						
	ENDOLOGIX INC.	  	US	  	ENDOLUMINAL VASCULAR PROSTHESIS	  	US20110218617A1	  	US13039157A	  	2011-03-02
						
	ENDOLOGIX INC	  	US	  	APPARATUS AND METHOD OF PLACEMENT OF A GRAFT OR GRAFT SYSTEM	  	US20110054587A1	  	US12769546A	  	2010-04-28

  
 15 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC	  	US	  	IMPLANTABLE VASCULAR GRAFT	  	US20100318174A1	  	US12860280A	  	2010-08-20
						
	ENDOLOGIX INC	  	US	  	IMPLANTABLE VASCULAR GRAFT	  	US20100318181A1	  	US12860310A	  	2010-08-20
						
	ENDOLOGIX INC.	  	US	  	UTILIZATION OF MURAL THROMBUS FOR LOCAL DRUG DELIVERY INTO VASCULAR TISSUE	  	US20100261662A1	  	US12757900A	  	2010-04-09
						
	ENDOLOGIX INC	  	US	  	GRAFT DEPLOYMENT SYSTEM	  	US20100179636A1	  	US12726257A	  	2010-03-17
						
	ENDOLOGIX INC.	  	US	  	STENT GRAFT DELIVERY SYSTEM	  	US20100036360A1	  	US12429474A	  	2009-04-24

  
 16 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC.	  	US	  	DOCKING APPARATUS AND METHODS OF USE	  	US20090319029A1	  	US12478208A	  	2009-06-04
						
	ENDOLOGIX INC.	  	US	  	GRAFT ENDOFRAME HAVING AXIALLY VARIABLE CHARACTERISTICS	  	US20100004728A1	  	US12371087A	  	2009-02-13
						
	ENDOLOGIX INC.	  	US	  	METHOD AND AGENT FOR IN-SITU STABILIZATION OF VASCULAR TISSUE	  	US20090155337A1	  	US12269677A	  	2008-11-12
						
	ENDOLOGIX INC.	  	US	  	STENT	  	US20090105806A1	  	US12257149A	  	2008-10-23
						
	ENDOLOGIX INC.	  	US	  	Multi-segmented graft deployment system	  	US20080071343A1	  	US11522292A	  	2006-09-15

  
 17 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC	  	US	  	IMPLANTABLE VASCULAR GRAFT	  	US20070299497A1	  	US11764715A	  	2007-06-18
						
	ENDOLOGIX INC.	  	US	  	Methods and systems for aneurysm treatment using filling structures	  	US20070150041A1	  	US11444603A	  	2006-05-31
						
	ENDOLOGIX INC	  	US	  	ENDOLUMINAL VASCULAR PROSTHESIS	  	US20070112412A1	  	US11623679A	  	2007-01-16
						
	ENDOLOGIX INC.	  	US	  	Method and apparatus for decompressing aneurysms	  	US20070078506A1	  	US11580201A	  	2006-10-12
						
	ENDOLOGIX INC.	  	US	  	Method and apparatus for decompressing aneurysms	  	US20050245891A1	  	US11104303A	  	2005-04-12

  
 18 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC.	  	US	  	Vascular stent-graft apparatus	  	US20040167607A1	  	US10787404A	  	2004-02-24
						
	ENDOLOGIX INC.	  	US	  	Stent-graft with positioning anchor	  	US20040116997A1	  	US10668901A	  	2003-09-22
						
	ENDOLOGIX INC.	  	US	  	Flexible vascular graft	  	US20010025195A1	  	US09728582A	  	2000-12-01
						
	ENDOLOGIX INC	  	US	  	MODULAR STENT GRAFT SYSTEMS AND METHODS WITH INFLATABLE FILL STRUCTURES	  	US20170239035A1	  	US15310198A	  	2016-11-10
						
	ENDOLOGIX INC	  	US	  	DUAL INFLATABLE ARTERIAL PROSTHESIS	  	US20180021045A1	  	US15540246A	  	2017-06-27

  
 19 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC	  	US	  	ENDOLUMINAL PROSTHESIS SYSTEMS AND METHODS	  		  	US15737223	  	2017-12-15
						
	ENDOLOGIX INC	  	US	  	Systems and Methods with Stents and Filling Structure	  		  	62/382207	  	2016-08-31
						
	ENDOLOGIX INC	  	US	  	STENTS, GRAFTS, DELIVERY SYSTEMS, AND METHODS	  		  	62/481560	  	2017-04-04
						
	ENDOLOGIX INC	  	US	  	ENDOVASCULAR SYSTEMS, DEVICES, AND METHODS ALLOWING FOR BRANCH DEVICE PLACEMENT IN POCKET OF MAIN GRAFT	  		  	62/489213	  	2017-04-24
						
	ENDOLOGIX INC	  	US	  	ENDOVASCULAR GRAFT SYSTEMS AND METHODS FOR DEPLOYMENT IN MAIN AND BRANCH ARTERIES	  		  	62/529669	  	2017-07-07

  
 20 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC	  	US	  	STENT GRAFTS AND METHODS OF ENHANCING FLEXIBILITY OF STENT GRAFTS BY THERMAL PLEATING	  		  	62/532737	  	2017-07-14
						
	ENDOLOGIX INC	  	US	  	STENT GRAFT	  		  	15/911629	  	2018-03-05
						
	ENDOLOGIX INC	  	US	  	INTERNAL ILIAC PRESERVATION DEVICES AND METHODS	  		  	15/965649	  	2018-04-
						
	ENDOLOGIX INC	  	US	  	MODULATION OF INFLAMMATORY RESPONSE FOLLOWING ENDOVASCULAR TREATMENT	  		  	62/661569	  	2018-4-23
						
	ENDOLOGIX INC	  	US	  	ADVANCED KINK RESISTANT STENT GRAFT	  		  	16/005269	  	2018-6-11

  
 21 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC	  	US	  	LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM	  		  	15/985572	  	2018-5-21
						
	ENDOLOGIX INC	  	US	  	SYSTEMS AND METHODS WITH STENT AND FILLING STRUCTURE	  		  	15/774511	  	2017-8-30
						
	ENDOLOGIX INC	  	US	  	LONGITUDINALLY EXTENDABLE STENT GRAFT SYSTEMS AND METHODS	  		  	15/774548	  	2018-1-23
						
	ENDOLOGIX INC	  	US	  	GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS AND METHODS FOR THEIR USE	  		  	16/035497	  	2018-7-13
						
	ENDOLOGIX INC	  	US	  	PRE-FIXATION DEVICE FOR NELLIX AND OTHER EVAS DEVICES	  		  	62/678956	  	2018-5-31

  
 22 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC	  	US	  	SYSTEMS AND METHODS WITH FENESTRATED GRAFT AND FILLING STRUCTURE	  		  	16/066595	  	
						
	ENDOLOGIX INC	  	US	  	MODULATION OF INFLAMMATORY RESPONSE FOLLOWING ENDOVASCULAR TREATMENT	  		  	62/661569	  	2018-4-23
						
	ENDOLOGIX INC.	  	US	  	FENESTRATED PROSTHESIS	  	US8945202	  	12/769581	  	2015-2-3
						
	ENDOLOGIX INC.	  	US	  	Fenestrated prosthesis	  	US8945202	  	12/769581	  	4/28/10
						
	ENDOLOGIX, INC.	  	US	  	Bifurcated vascular graft deployment device	  	US6210422	  	09/505038	  	2/16/00

  
 23 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX, INC.	  	US	  	Method of deploying bifurcated vascular graft	  	US6156063	  	09/086247	  	5/28/98
						
	ENDOLOGIX, INC.	  	US	  	Bifurcated vascular graft deployment device	  	US6090128	  	08/802478	  	2/20/97
						
	ENDOLOGIX, INC.	  	US	  	Endovascular prosthesis with improved sealing means for aneurysmal arterial disease and method of use	  	US5665117	  	08/620072	  	3/21/96
						
	ENDOLOGIX, INC.	  	US	  	Locking assembly for coupling guidewire to delivery system	  		  	15/317905	  	12/9/16
						
	Endologix, Inc. and The Cleveland Clinic Foundation	  	US	  	Fenestrated prosthesis	  	US8945202	  	US12769581	  	4/28/10

  
 24 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	Endologix, Inc.	  	US	  	Single puncture bifurcation graft deployment system	  	US7691135	  	US10690227	  	10/21/03
						
	Endologix, Inc.	  	US	  	Bifurcated vascular graft and method and apparatus for deploying same	  	US6951572	  	US10639255	  	8/12/03
						
	Endologix, Inc.	  	US	  	Radiation delivery balloon catheter	  	US6699170	  	US09688396	  	10/16/00
						
	Endologix, Inc.	  	US	  	Dual wire placement catheter	  	US6689157	  	US10035729	  	12/21/01
						
	Endologix, Inc.	  	US	  	Method for delivering radiation to an intraluminal site in the body	  	US6685618	  	US09944649	  	8/31/01

  
 25 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	Endologix, Inc.	  	US	  	Radiation delivery catheters and dosimetry methods	  	US6491619	  	US09648563	  	8/25/00
						
	Endologix, Inc.	  	US	  	Endoluminal vascular prosthesis	  	US6331190	  	US09483411	  	1/14/00
						
	Endologix, Inc.	  	US	  	Bifurcated vascular graft deployment device	  	US6210422	  	US09505038	  	2/16/00
						
	Endologix, Inc.	  	US	  	Method of deploying bifurcated vascular graft	  	US6156063	  	US09086247	  	5/28/98
						
	Endologix, Inc.	  	US	  	Bifurcated vascular graft deployment device	  	US6090128	  	US08802478	  	2/20/97

  
 26 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	Endologix, Inc.	  	US	  	Axially non-contracting flexible radially expandable stent	  	US6083259	  	US09192803	  	11/16/98
						
	Endologix, Inc.	  	US	  	Endovascular prosthesis with improved sealing means for aneurysmal arterial disease and method of use	  	US5665117	  	US08620072	  	3/21/96
						
	Endologix, Inc.	  	US	  	Apparatus and method of placement of a graft or graft system	  		  	US14172126	  	2/4/14
						
	Endologix, Inc. and The Cleveland Clinic Foundation	  	US	  	Apparatus and method of placement of a graft or graft system	  		  	US12769506	  	4/28/10
						
	Endologix, Inc.	  	US	  	Stent graft delivery system	  		  	US12429474	  	4/24/09

  
 27 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	ENDOLOGIX INC	  	US	  	ENDOLUMINAL DEVICE AND POLYMER	  		  	62/575827	  	2017-10-23
						
	TRIVASCULAR INC	  	US	  	Advanced Endovascular Graft	  	US9788934B2	  	US14799656A	  	2015-07-15
						
	NELLIX INC.	  	US	  	Stent-graft with positioning anchor	  	US9814612B2	  	US14697433A	  	2015-10-21
						
	NELLIX INC.	  	US	  	System and methods for endovascular aneurysm treatment	  	US9737425B2	  	US14537749A	  	2014-11-10
						
	NELLIX INC.	  	US	  	Stent graft delivery system	  	US9730700B2	  	US14586110A	  	2015-04-23

  
 28 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	NELLIX INC.	  	US	  	Methods for deploying a positioning anchor with a stent-graft	  	US9113999B2	  	US11876458A	  	2007-10-22
						
	NELLIX INC.	  	US	  	Sealing apparatus and methods of use	  	US8945199B2	  	US12478225A	  	2009-06-04
						
	NELLIX INC.	  	US	  	Stent graft delivery system	  	US8926682B2	  	US13243941A	  	2011-09-23
						
	NELLIX INC.	  	US	  	System and methods for endovascular aneurysm treatment	  	US8906084B2	  	US12684074A	  	2010-01-07
						
	NELLIX INC.	  	US	  	Graft systems having filling structures supported by scaffolds and methods for their use	  	US8870941B2	  	US13285897A	  	2011-10-31

  
 29 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	NELLIX INC.	  	US	  	STENT GRAFT DELIVERY SYSTEM	  	US20180028192A1	  	US15676869A	  	2017-08-14
						
	NELLIX INC.	  	US	  	SEALING APPRATUS AND METHODS OF USE	  	US20150148892A1	  	US14612048A	  	2015-02-02
						
	NELLIX INC.	  	US	  	GRAFT SYSTEMS HAVING FILLING STRUCTURES SUPPORTED BY SCAFFOLDS AND METHODS FOR THEIR USE	  	US10022249	  	US14525019A	  	2014-10-27
						
	NELLIX, INC.	  	US	  	System and methods of Endovascular Aneurysm Treatment	  		  	14/682414	  	8/21/17
						
	Nellix, Inc.	  	US	  	Vascular stent-graft apparatus and forming method	  	US6695833	  	US09671550	  	9/27/00

  
 30 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	Endovascular graft	  	US9867727B2	  	US14320773A	  	2014-07-01
						
	TRIVASCULAR INC.	  	US	  	Advanced endovascular graft	  	US9788934B2	  	US14799656A	  	2015-07-15
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft for aneurysms involving major branch vessels	  	US9724186B2	  	US14050835A	  	2013-10-10
						
	TRIVASCULAR INC.	  	US	  	System and method of pivoted stent deployment	  	US9713523B2	  	US14452343A	  	2014-08-05
						
	TRIVASCULAR INC.	  	US	  	Systems and methods for guidewire crossover for bifurcated prostheses	  	US9655754B2	  	US14323059A	  	2014-07-03

  
 31 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	Bifurcated endovascular prosthesis having tethered contralateral leg	  	US9585774B2	  	US14823076A	  	2015-08-11
						
	TRIVASCULAR INC.	  	US	  	PTFE layers and methods of manufacturing	  	US9549829B2	  	US14458349A	  	2014-08-13
						
	TRIVASCULAR INC.	  	US	  	Delivery catheter for endovascular device	  	US9498363B2	  	US13835491A	  	2013-03-15
						
	TRIVASCULAR INC	  	US	  	Low profile stent and delivery system	  	US9463101B2	  	US14923477A	  	2015-10-27
						
	TRIVASCULAR INC.	  	US	  	PTFE layers and methods of manufacturing	  	US9446553B2	  	US14230318A	  	2014-03-31

  
 32 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	Endovascular graft joint and method for manufacture	  	US9351858B2	  	US14704013A	  	2015-05-05
						
	TRIVASCULAR INC.	  	US	  	Non-degradable, low swelling, water soluble radiopaque hydrogel polymer	  	US9308301B2	  	US13089960A	  	2011-04-19
						
	TRIVASCULAR INC.	  	US	  	Endovascular delivery system with an improved radiopaque marker scheme	  	US9233015B2	  	US13803050A	  	2013-03-14
						
	TRIVASCULAR INC.	  	US	  	Low profile stent graft and delivery system	  	US9192462B2	  	US13803037A	  	2013-03-14
						
	TRIVASCULAR INC.	  	US	  	Fenestrated inflatable graft	  	US9144486B2	  	US13652471A	  	2012-10-15

  
 33 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	Bifurcated endovascular prosthesis having tethered contralateral leg	  	US9132025B2	  	US13803067A	  	2013-03-14
						
	TRIVASCULAR INC.	  	US	  	Endovascular delivery system with flexible and torqueable hypotube	  	US9066828B2	  	US13803062A	  	2013-03-14
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft joint and method for manufacture	  	US9050754B2	  	US12729182A	  	2010-03-22
						
	TRIVASCULAR INC.	  	US	  	Durable stent graft with tapered struts and stable delivery methods and devices	  	US8992595B2	  	US13799207A	  	2013-03-13
						
	TRIVASCULAR INC.	  	US	  	In vitro testing of endovascular device	  	US8978448B2	  	US13649066A	  	2012-10-10

  
 34 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	Advanced endovascular graft delivery system and method of treatment	  	US8900288B2	  	US12566104A	  	2009-09-24
						
	TRIVASCULAR INC.	  	US	  	Method of delivering advanced endovascular graft and system	  	US8864814B2	  	US13246651A	  	2011-09-27
						
	TRIVASCULAR INC.	  	US	  	PTFE layers and methods of manufacturing	  	US8840824B2	  	US12910281A	  	2010-10-22
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft	  	US8801769B2	  	US13737351A	  	2013-01-09
						
	TRIVASCULAR INC.	  	US	  	Apparatus for manufacturing an endovascular graft section	  	US8783316B2	  	US12697504A	  	2010-02-01

  
 35 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	PTFE layers and methods of manufacturing	  	US8728372B2	  	US12915636A	  	2010-10-29
						
	TRIVASCULAR INC.	  	US	  	Advanced endovascular graft	  	US8709065B2	  	US12491336A	  	2009-06-25
						
	TRIVASCULAR INC.	  	US	  	Virtual prototyping and testing for medical device development	  	US8666714B2	  	US13523765A	  	2012-06-14
						
	TRIVASCULAR INC.	  	US	  	Asymmetric stent apparatus and method	  	US8663309B2	  	US11861828A	  	2007-09-26
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft	  	US8361136B2	  	US12566793A	  	2009-09-25

  
 36 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	Endovascular graft joint and method for manufacture	  	US8348989B2	  	US11429735A	  	2006-05-08
						
	TRIVASCULAR INC.	  	US	  	Delivery system and method for bifurcated graft	  	US8328861B2	  	US11941434A	  	2007-11-16
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft and method of delivery	  	US8241346B2	  	US13246643A	  	2011-09-27
						
	TRIVASCULAR INC.	  	US	  	Inflatable porous implants and methods for drug delivery	  	US8267989B2	  	US12860364A	  	2010-08-20
						
	TRIVASCULAR INC.	  	US	  	Inflatable intraluminal graft	  	US8226708B1	  	US10168053A	  	2002-06-14

  
 37 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	Stent and delivery system for deployment thereof	  	US8226701B2	  	US11861756A	  	2007-09-26
						
	TRIVASCULAR INC.	  	US	  	Virtual prototyping and testing for medical device development	  	US8224632B2	  	US12904994A	  	2010-10-14
						
	TRIVASCULAR INC.	  	US	  	Dual chamber cuff structure	  	US8216297B2	  	US11504434A	  	2006-08-14
						
	TRIVASCULAR INC.	  	US	  	Barbed radially expandable stent	  	US8167927B2	  	US13245661A	  	2011-09-26
						
	TRIVASCULAR INC.	  	US	  	Securement assembly and method for expandable endovascular device	  	US8083789B2	  	US11941450A	  	2007-11-16

  
 38 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	System and method of pivoted stent deployment	  	US8066755B2	  	US11861716A	  	2007-09-26
						
	TRIVASCULAR INC.	  	US	  	Constant force material delivery system and method	  	US7971751B2	  	US12724068A	  	2010-03-15
						
	TRIVASCULAR INC.	  	US	  	Passive hemostatic sheath valve	  	US7901379B2	  	US11298285A	  	2005-12-09
						
	TRIVASCULAR INC.	  	US	  	Virtual prototyping and testing for medical device development	  	US7840393B1	  	US09679725A	  	2000-10-04
						
	TRIVASCULAR INC.	  	US	  	Inflatable porous implants and methods for drug delivery	  	US7803178B2	  	US10769532A	  	2004-01-30

  
 39 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	Advanced endovascular graft	  	US7766954B2	  	US11333595A	  	2006-01-17
						
	TRIVASCULAR INC.	  	US	  	Constant force material delivery system and method	  	US7708163B2	  	US11360077A	  	2006-02-23
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft joint and method for manufacture	  	US7682475B2	  	US11870748A	  	2007-10-11
						
	TRIVASCULAR INC.	  	US	  	Method for manufacturing an endovascular graft section	  	US7678217B2	  	US11522490A	  	2006-09-15
						
	TRIVASCULAR INC.	  	US	  	Inflatable implant	  	US7632291B2	  	US10461853A	  	2003-06-13

  
 40 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	Endovascular graft	  	US7615071B2	  	US11390732A	  	2006-03-28
						
	TRIVASCULAR INC.	  	US	  	Delivery system and method for expandable intracorporeal device	  	US7338518B2	  	US11201028A	  	2005-08-10
						
	TRIVASCULAR INC.	  	US	  	Passive hemostatic sheath valve	  	US7241276B2	  	US10636871A	  	2003-08-06
						
	TRIVASCULAR INC.	  	US	  	Advanced endovascular graft	  	US7147660B2	  	US10327711A	  	2002-12-20
						
	TRIVASCULAR INC.	  	US	  	Kink resistant endovascular graft	  	US7150758B2	  	US10384103A	  	2003-03-06

  
 41 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	Radially expandable stent	  	US7147661B2	  	US10029559A	  	2001-12-20
						
	TRIVASCULAR INC.	  	US	  	Method and apparatus for shape forming endovascular graft material	  	US7147455B2	  	US10868292A	  	2004-06-14
						
	TRIVASCULAR INC.	  	US	  	Method for manufacturing an endovascular graft section	  	US7125464B2	  	US10029557A	  	2001-12-20
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft	  	US7081129B2	  	US10132754A	  	2002-04-24
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft joint and method for manufacture	  	US7090693B1	  	US10029584A	  	2001-12-20

  
 42 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	Delivery system and method for expandable intracorporeal device	  	US7066951B2	  	US10419312A	  	2003-04-17
						
	TRIVASCULAR INC.	  	US	  	Method and apparatus for shape forming endovascular graft material	  	US6776604B1	  	US10029570A	  	2001-12-20
						
	TRIVASCULAR INC.	  	US	  	Delivery system and method for bifurcated endovascular graft	  	US6761733B2	  	US09917371A	  	2001-07-27
						
	TRIVASCULAR INC.	  	US	  	Delivery system and method for endovascular graft	  	US6733521B2	  	US09834278A	  	2001-04-11
						
	TRIVASCULAR INC.	  	US	  	Delivery system and method for expandable intracorporeal device	  	US6602280B2	  	US09774733A	  	2001-01-31

  
 43 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	Endovascular graft	  	US6395019B2	  	US09133978A	  	1998-08-14
						
	TRIVASCULAR INC	  	US	  	ENDOVASCULAR GRAFT	  	US20170348125A1	  	US15686214A	  	2017-08-25
						
	TRIVASCULAR INC	  	US	  	ADVANCED ENDOVASCULAR GRAFT	  	US20170348087A1	  	US15686218A	  	2017-08-25
						
	TRIVASCULAR INC	  	US	  	ENDOVASCUALR GRAFT FOR ANEURYSMS INVOLVING MAJOR BRANCH VESSELS	  	US20170296327A1	  	US15638559A	  	2017-06-30
						
	TRIVASCULAR INC	  	US	  	SYSTEMS AND METHODS FOR GUIDEWIRE CROSSOVER FOR BIFURCATED PROSTHESES	  	US20170216064A1	  	US15491074A	  	2017-04-19

  
 44 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC	  	US	  	Low Profile Stent Graft and Delivery System	  	US9987123	  	US15263469A	  	2016-09-13
						
	TRIVASCULAR INC	  	US	  	BIFURCATED ENDOVASCULAR PROSTHESIS HAVING TETHERED CONTRALATERAL LEG	  	US20170035549A1	  	US15299542A	  	2016-10-21
						
	TRIVASCULAR INC.	  	US	  	DELIVERY CATHETER FOR ENDOVASCULAR DEVICE	  	US20170035590A1	  	US15298166A	  	2016-10-19
						
	TRIVASCULAR INC	  	US	  	PTFE LAYERS AND METHODS OF MANUFACTURING	  	US20160367354A1	  	US15251011A	  	2016-08-30
						
	TRIVASCULAR INC	  	US	  	ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME	  	US10034787	  	US14970621A	  	2015-12-16

  
 45 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC	  	US	  	NON-DEGRADABLE, LOW SWELLING, WATER SOLUBLE RADIOPAQUE HYDROGEL POLYMER	  	US20160193392A1	  	US15068415A	  	2016-03-11
						
	TRIVASCULAR INC.	  	US	  	INTERNAL ILIAC PRESERVATION DEVICES AND METHODS	  	US9956101	  	US14958085A	  	2015-12-03
						
	TRIVASCULAR INC.	  	US	  	STENT GRAFT DELIVERY SYSTEM WITH ACCESS CONDUIT	  	US20160113796A1	  	US14920828A	  	2015-10-22
						
	TRIVASCULAR INC.	  	US	  	ENDOVASCULAR DELIVERY SYSTEM WITH FLEXIBLE AND TORQUEABLE HYPOTUBE	  	US20150265446A1	  	US14717080A	  	2015-05-20
						
	TRIVASCULAR INC.	  	US	  	INFLATABLE OCCLUSION WIRE-BALLOON FOR AORTIC APPLICATIONS	  	US20150250481A1	  	US14643217A	  	2015-03-10

  
 46 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM	  	US20150164667A1	  	US14631818A	  	2015-02-25
						
	TRIVASCULAR INC.	  	US	  	DURABLE STENT GRAFT WITH TAPERED STRUTS AND STABLE DELIVERY METHODS AND DEVICES	  	US20150157479A1	  	US14615337A	  	2015-02-05
						
	TRIVASCULAR INC.	  	US	  	TANDEM MODULAR ENDOGRAFT	  	US20150088244A1	  	US14492674A	  	2014-09-22
						
	TRIVASCULAR INC.	  	US	  	ENDOLEAK ISOLATION SLEEVES AND METHODS OF USE	  	US20150073523A1	  	US14481834A	  	2014-09-09
						
	TRIVASCULAR INC.	  	US	  	GATE WIRE FOR CONTRALATERAL LEG ACCESS	  	US20140194970A1	  	US14151373A	  	2014-01-09

  
 47 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	SAC LINER FOR ANEURYSM REPAIR	  	US20140194973A1	  	US14151195A	  	2014-01-09
						
	TRIVASCULAR INC.	  	US	  	ASYMMETRIC STENT APPARATUS AND METHOD	  	US20140135899A1	  	US14157350A	  	2014-01-16
						
	TRIVASCULAR INC.	  	US	  	LOW PROFILE STENT GRAFT AND DELIVERY SYSTEM	  	US20130268056A1	  	US13803033A	  	2013-03-14
						
	TRIVASCULAR INC.	  	US	  	ADVANCED KINK RESISTANT STENT GRAFT	  	US9993328	  	US13803046A	  	2013-03-14
						
	TRIVASCULAR INC.	  	US	  	VASCULAR GRAFT HAVING LIMITED END STRUCTURE	  	US20130096665A1	  	US13650705A	  	2012-10-12

  
 48 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	INFLATABLE INTRALUMINAL GRAFT	  	US20120265290A1	  	US13532887A	  	2012-06-26
						
	TRIVASCULAR INC.	  	US	  	ADVANCED ENDOVASCULAR GRAFT AND DELIVERY SYSTEM	  	US20120191174A1	  	US13297219A	  	2011-11-15
						
	TRIVASCULAR INC.	  	US	  	SYSTEM AND METHOD OF PIVOTED STENT DEPLOYMENT	  	US20120083870A1	  	US13277117A	  	2011-10-19
						
	TRIVASCULAR INC.	  	US	  	BARBED RADIALLY EXPANDABLE STENT WITH SLOTTED STRUTS	  	US20120016457A1	  	US13245652A	  	2011-09-26
						
	TRIVASCULAR INC.	  	US	  	FILL TUBE MANIFOLD AND DELIVERY METHODS FOR ENDOVASCULAR GRAFT	  	US20110218609A1	  	US13024255A	  	2011-02-09

  
 49 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	HINGED ENDOVASCULAR DEVICE	  	US20100331958A1	  	US12747499A	  	2010-09-07
						
	TRIVASCULAR INC.	  	US	  	Inflatable Implant	  	US20100076481A1	  	US12628623A	  	2009-12-01
						
	TRIVASCULAR INC.	  	US	  	METHOD OF DELIVERING ADVANCED ENDOVASCULAR GRAFT	  	US20100016943A1	  	US12566808A	  	2009-09-25
						
	TRIVASCULAR INC.	  	US	  	MODULAR VASCULAR GRAFT FOR LOW PROFILE PERCUTANEOUS DELIVERY	  	US20090099649A1	  	US12245620A	  	2008-10-03
						
	TRIVASCULAR INC.	  	US	  	ALIGNMENT STENT APPARATUS AND METHOD	  	US20090082845A1	  	US11861746A	  	2007-09-26

  
 50 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	SYSTEM AND METHOD OF SECURING STENT BARBS	  	US20090082847A1	  	US11861731A	  	2007-09-26
						
	TRIVASCULAR INC.	  	US	  	APPARATUS FOR SECURING STENT BARBS	  	US20090082841A1	  	US11861739A	  	2007-09-26
						
	TRIVASCULAR INC.	  	US	  	PTFE LAYERS AND METHODS OF MANUFACTURING	  	US20090036971A1	  	US12250915A	  	2008-10-14
						
	TRIVASCULAR INC.	  	US	  	PTFE LAYERS AND METHODS OF MANUFACTURING	  	US20090036973A1	  	US12250946A	  	2008-10-14
						
	TRIVASCULAR INC.	  	US	  	Non-degradable, low swelling, water soluble radiopaque hydrogel polymer	  	US20060222596A1	  	US11097467A	  	2005-04-01

  
 51 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	Hybrid modular endovascular graft	  	US20060224232A1	  	US11097718A	  	2005-04-01
						
	TRIVASCULAR INC.	  	US	  	Delivery system and method for bifurcated graft	  	US20060009833A1	  	US11205793A	  	2005-08-15
						
	TRIVASCULAR INC.	  	US	  	Methods, compositions and devices for embolizing body lumens	  	US20050158272A1	  	US11031311A	  	2005-01-07
						
	TRIVASCULAR INC.	  	US	  	Endoluminal prosthesis endoleak management	  	US20050090804A1	  	US10691849A	  	2003-10-22
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft joint and method for manufacture	  	US20050027347A1	  	US10640368A	  	2003-08-13

  
 52 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	Layered endovascular graft	  	US20040220664A1	  	US10803153A	  	2004-03-17
						
	TRIVASCULAR INC.	  	US	  	Delivery system and method for bifurcated graft	  	US20040138734A1	  	US10686863A	  	2003-10-16
						
	TRIVASCULAR INC.	  	US	  	Endovascular graft	  	US20030216802A1	  	US10289136A	  	2002-11-05
						
	TRIVASCULAR INC.	  	US	  	Inflatable intraluminal graft	  	US20030225453A1	  	US10289137A	  	2002-11-05
						
	TRIVASCULAR INC.	  	US	  	Advanced endovascular graft	  	US20030120338A1	  	US10091641A	  	2002-03-05

  
 53 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	TRIVASCULAR INC.	  	US	  	Delivery system and method for bifurcated graft	  	US20030004560A1	  	US10122474A	  	2002-04-11
						
	TRIVASCULAR INC.	  	US	  	Layered endovascular graft	  	US20020010508A1	  	US09970576A	  	2001-10-04
						
	TRIVASCULAR, INC.	  	US	  	Stent-graft with improved flexibility	  		  	15/568834	  	10/24/17
						
	Trivascular, Inc.	  	US	  	Passive hemostatic sheath valve	  	US7901379	  	US11298285	  	12/9/05
						
	Trivascular, Inc.	  	US	  	Fluid mixing apparatus and method	  	US7178978	  	US10658074	  	9/8/03

  
 54 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	Trivascular, Inc.	  	US	  	Delivery system and method for expandable intracorporeal device	  	US6602280	  	US09774733	  	1/31/01
						
	Trivascular, Inc.	  	US	  	Endovascular graft	  	US6395019	  	US09133978	  	8/14/98
						
	Trivascular, Inc.	  	US	  	Layered endovascular graft	  	US6331191	  	US09200317	  	11/25/98
						
	Trivascular, Inc.	  	US	  	Endovascular graft having longitudinally displaceable sections	  	US6132457	  	US09177295	  	10/22/98
						
	Trivascular, Inc.	  	US	  	Low profile stent graft and delivery system	  		  	US15263469	  	9/13/16

  
 55 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	Trivascular, Inc.	  	US	  	Delivery catheter for endovascular device	  		  	US15298166	  	10/19/16
						
	Trivascular, Inc.	  	US	  	Bifurcated endovascular prosthesis having tethered contralateral leg	  		  	US15299542	  	10/21/16
						
	Trivascular, Inc.	  	US	  	Ptfe layers and methods of manufacturing	  		  	US15251011	  	8/30/16
						
	Trivascular, Inc.	  	US	  	Endovascular delivery system with an improved radiopaque marker scheme	  		  	US14970621	  	12/16/15
						
	Trivascular, Inc.	  	US	  	Non-degradable, low swelling, water soluble radiopaque hydrogel polymer	  		  	US15068415	  	3/11/16

  
 56 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	Trivascular, Inc.	  	US	  	Internal iliac preservation devices and methods	  		  	US14958085	  	12/3/15
						
	Trivascular, Inc.	  	US	  	Stent graft delivery system with access conduit	  		  	US14920828	  	10/22/15
						
	Trivascular, Inc.	  	US	  	Bifurcated endovascular prosthesis having tethered contralateral leg	  		  	US14823076	  	8/11/15
						
	Trivascular, Inc.	  	US	  	Low profile stent and delivery system	  		  	US14923477	  	10/27/15
						
	Trivascular, Inc.	  	US	  	Endovascular delivery system with flexible and torqueable hypotube	  		  	US14717080	  	5/20/15

  
 57 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	Trivascular, Inc.	  	US	  	Inflatable occlusion wire-balloon for aortic applications	  		  	US14643217	  	3/10/15
						
	Trivascular, Inc.	  	US	  	Advanced endovascular graft and delivery system	  		  	US14631818	  	2/25/15
						
	Trivascular, Inc.	  	US	  	Durable stent graft with tapered struts and stable delivery methods and devices	  		  	US14615337	  	2/5/15
						
	Trivascular, Inc.	  	US	  	Tandem modular endograft	  		  	US14492674	  	9/22/14
						
	Trivascular, Inc.	  	US	  	Endoleak isolation sleeves and methods of use	  		  	US14481834	  	9/9/14

  
 58 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	Trivascular, Inc.	  	US	  	Sac liner for aneurysm repair	  		  	US14151195	  	1/9/14
						
	Trivascular, Inc.	  	US	  	Gate wire for contralateral leg access	  		  	US14151373	  	1/9/14
						
	Trivascular, Inc.	  	US	  	Asymmetric stent apparatus and method	  		  	US14157350	  	1/16/14
						
	Trivascular, Inc.	  	US	  	Low profile stent graft and delivery system	  		  	US13803033	  	3/14/13
						
	Trivascular, Inc.	  	US	  	Advanced kink resistant stent graft	  		  	US13803046	  	3/14/13

  
 59 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	Trivascular, Inc.	  	US	  	Vascular graft having limited end structure	  		  	US13650705	  	10/12/12
						
	Trivascular, Inc.	  	US	  	Inflatable intraluminal graft	  		  	US13532887	  	6/26/12
						
	Trivascular, Inc.	  	US	  	Advanced endovascular graft and delivery system	  		  	US13297219	  	11/15/01
						
	Trivascular, Inc.	  	US	  	System and method of pivoted stent deployment	  		  	US13277117	  	10/19/11
						
	Trivascular, Inc.	  	US	  	Barbed radially expandable stent with slotted struts	  		  	US13245652	  	9/26/11

  
 60 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	Trivascular, Inc.	  	US	  	Fill tube manifold and delivery methods for endovascular graft	  		  	US13024255	  	2/9/11
						
	Trivascular, Inc.	  	US	  	Hinged endovascular device	  		  	US12747499	  	9/7/10
						
	Trivascular, Inc.	  	US	  	Inflatable implant	  		  	US12628623	  	12/1/09
						
	Trivascular, Inc.	  	US	  	Method of delivering advanced endovascular graft	  		  	US12566808	  	9/25/09
						
	Trivascular, Inc.	  	US	  	Modular vascular graft for low profile percutaneous delivery	  		  	US12245620	  	10/3/08

  
 61 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	Trivascular, Inc.	  	US	  	System and method of securing stent barbs	  		  	US11861731	  	9/26/07
						
	Trivascular, Inc.	  	US	  	Alignment stent apparatus and method	  		  	US11861746	  	9/26/07
						
	Trivascular, Inc.	  	US	  	Apparatus for securing stent barbs	  		  	US11861739	  	9/26/07
						
	Trivascular, Inc.	  	US	  	Ptfe layers and methods of manufacturing	  		  	US12250946	  	10/14/08
						
	Trivascular, Inc.	  	US	  	Ptfe layers and methods of manufacturing	  		  	US12250915	  	10/14/08

  
 62 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	Trivascular, Inc.	  	US	  	Ptfe layers and methods of manufacturing	  		  	US11106150	  	4/13/05
						
	Trivascular, Inc.	  	US	  	Ptfe layers and methods of manufacturing	  		  	US11106131	  	4/13/05
						
	Trivascular, Inc.	  	US	  	Hybrid modular endovascular graft	  		  	US11097718	  	4/1/05
						
	Trivascular, Inc.	  	US	  	Non-degradable low swelling, water soluble radiopaque hydrogel polymer	  		  	US11097467	  	4/1/05
						
	Trivascular, Inc.	  	US	  	Delivery system and method for bifurcated graft	  		  	US11205793	  	8/15/05

  
 63 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	Trivascular, Inc.	  	US	  	Modular endovascular graft	  		  	US11077938	  	3/11/05
						
	Trivascular, Inc.	  	US	  	Methods, compositions and devices for embolizing body lumens	  		  	US11031311	  	1/7/05
						
	Trivascular, Inc.	  	US	  	Endoluminal prosthesis endoleak management	  		  	US10691849	  	10/22/03
						
	Trivascular, Inc.	  	US	  	Endovascular graft joint and method for manufacture	  		  	US10640368	  	8/13/03
						
	Trivascular, Inc.	  	US	  	Layered endovascular graft	  		  	US10803153	  	3/17/04

  
 64 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	Trivascular, Inc.	  	US	  	Delivery system and method for bifurcated graft	  		  	US10686863	  	10/16/03
						
	Trivascular, Inc.	  	US	  	Inflatable intraluminal graft	  		  	US10289137	  	11/5/02
						
	Trivascular, Inc.	  	US	  	Endovascular graft	  		  	US10289136	  	11/5/02
						
	Trivascular, Inc.	  	US	  	Advanced endovascular graft	  		  	US10091641	  	3/5/02
						
	Trivascular, Inc.	  	US	  	Delivery system and method for bifurcated graft	  		  	US10122474	  	4/11/02

  
 65 

											
	 Grantor
	  	 Country
	  	 Patent
	  	 Publication/Patent No.
	  	 Application Number
	  	 Application Date

	Trivascular, Inc.	  	US	  	Layered endovascular graft	  		  	US09970576	  	10/3/01
						
	ENDOLOGIX INC.	  	US	  	STENT GRAFT SYSTEMS WITH RESTRAINTS IN CIRCUMFERENTIAL CHANNELS AND METHODS THEREOF	  		  	62/678961	  	5/31/2018
						
	ENDOLOGIX INC.	  	US	  	PERCUTANEOUS METHOD AND DEVICE TO TREAT DISSECTIONS	  		  	15/429090	  	2/9/2017
						
	NELLIX, INC.	  	US	  	SYSTEM AND METHODS FOR ENDOVASCULAR ANEURYSM TREATMENT	  	2018-0064566	  	15/682414	  	8/21/2017
						
	TRIVASCULAR INC.	  	US	  	ENDOVASCULAR DELIVERY SYSTEM WITH AN IMPROVED RADIOPAQUE MARKER SCHEME	  		  	16/049560	  	7/30/2018

  

  
 66

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]